Asset Details
Do you wish to reserve the book?
SAT0143 The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SAT0143 The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy
Do you wish to request the book?
SAT0143 The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SAT0143 The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy
2018
Overview
Background:One of the well-known characteristics of rheumatoid arthritis (RA) is generalized bone loss.1–2 Although rituximab is a frequently prescribed biologic disease-modifying anti-rheumatic drug (bDMARD) for the treatment of RA, data regarding changes in bone mineral density (BMD) in RA patients during rituximab therapy are limited.Objectives:To study the extent of BMD loss at lumbar spine and hip in patients with active rheumatoid arthritis treated with rituximab.Methods:Consecutive RA patients with an active disease status (DAS28>3.2) starting rituximab treatment were enrolled in a prospective cohort study. BMD of the lumbar spine and hip was measured before treatment and after one year using dual energy X-ray absorptiometry (DXA) to assess BMD changes. Clinical response was defined using the European League Against Rheumatism (EULAR) response criteria.Results:A total of 43 subjects (18.6% men) with mean age of 53.6 (SD 10.7) years were included in the study. Median disease duration was 9.5 (IQR 0.7–40.2) years and baseline mean DAS28 was 5.6 (SD 1.3). In responders, the DAS28 decreased with 1.97 points (SD 0.78) 95% CI 1.67 – 2.28 p<0.001; and in non-responders, the DAS28 decreased with 0.01 points (SD 0.67) 95% CI -0.35 – 0.37 p=0.945. All changes in BMD were not statistically significant (table 1).Table 1BMD change after one year categorized by EULAR responseConclusions:The findings of this study indicate that patients with active RA treated with rituximab have arrest of bone loss at both the lumbar spine and hip. Moreover, these results suggest that rituximab has bone-saving abilities even in the absence of clinical response.References[1] McInnes IB, et al. The New England journal of medicine2011;365:2205–2219.[2] Firestein GS, et al. Nature2003;423:356–361.Disclosure of Interest:None declared
Publisher
Elsevier Limited
